Roche has launched a new PCR test, cobas BV/CV, to diagnose bacterial vaginosis (BV) and candida vaginitis (CV) accurately. This test identifies specific bacteria and yeast in vaginal samples, improving diagnostic accuracy. The test offers faster diagnosis using a single swab for broader sexual health testing, streamlining the process. Traditional methods often result in inaccurate diagnoses, leading to delayed or inappropriate treatment. The cobas BV/CV assay delivers precise results, allowing for quicker, targeted therapies. Bacterial vaginosis affects roughly 25% of women, while candida vaginitis impacts up to 75% at some point in their lives. These conditions, causing uncomfortable symptoms, can also increase STI risks. The global sexual health market, with vaginitis as a primary driver, is experiencing significant growth. The cobas BV/CV test expands Roche's sexual health portfolio, enabling efficient testing on the cobas 5800/6800/8800 systems. The test is now available in countries accepting the CE Mark.